Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bellicum Pharma Comm (BLCM)

Bellicum Pharma Comm (BLCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,338
  • Shares Outstanding, K 5,050
  • Annual Sales, $ 7,140 K
  • Annual Income, $ -112,480 K
  • 60-Month Beta 2.18
  • Price/Sales 6.29
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -5.80
  • Growth Rate Est. (year over year) +17,324.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.91 +78.82%
on 05/06/20
9.56 -8.16%
on 06/05/20
+3.89 (+79.55%)
since 05/05/20
3-Month
3.32 +164.46%
on 03/16/20
9.56 -8.16%
on 06/05/20
-0.07 (-0.79%)
since 03/05/20
52-Week
3.32 +164.46%
on 03/16/20
27.90 -68.53%
on 01/17/20
-10.12 (-53.54%)
since 06/05/19

Most Recent Stories

More News
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 7.17 (+4.37%)
ALIM : 5.03 (+0.20%)
ANVS : 5.32 (+19.55%)
AQB : 2.63 (-5.40%)
ARTL : 1.3100 (+3.97%)
AVLNF : 0.0433 (-3.78%)
BLCM : 8.78 (-1.35%)
NDRA : 0.9275 (-0.27%)
EFOI : 1.2900 (+10.26%)
EQ : 2.96 (-2.63%)
EXROF : 0.6700 (+21.82%)
HL : 3.18 (-3.05%)
HSII : 24.07 (+2.95%)
HSDT : 0.5338 (+0.72%)
HGBL : 1.4800 (+5.71%)
IPWR : 2.47 (-1.18%)
LINC : 4.18 (+0.72%)
MBII : 1.0400 (+4.11%)
MLSS : 2.07 (+1.97%)
MYSZ : 1.1800 (-10.61%)
NBEV : 1.7100 (+6.21%)
ONCS : 2.19 (-2.67%)
OGEN : 0.5860 (+5.55%)
SFE : 7.39 (+0.96%)
SLS : 3.41 (+0.29%)
PIXY : 5.49 (+1.86%)
SGLB : 2.67 (-2.20%)
SOTK : 2.2600 (-1.74%)
TNXP : 0.6800 (+4.62%)
TGA : 0.6330 (+6.76%)
URG : 0.5638 (-1.33%)
Top Ranked Momentum Stocks to Buy for June 1st

Top Ranked Momentum Stocks to Buy for June 1st

FLWS : 22.82 (+0.62%)
BLCM : 8.78 (-1.35%)
BAND : 115.00 (+1.41%)
AGFS : 3.21 (+4.90%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of...

BLCM : 8.78 (-1.35%)
Bellicum Announces Publication of Data for GoCAR-NK(TM) Cell Program

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of preclinical data from its GoCAR-NK(TM)...

BLCM : 8.78 (-1.35%)
Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor...

BLCM : 8.78 (-1.35%)
All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BLCM : 8.78 (-1.35%)
Rapha Capital Management Leads Series A Financing for FIZE Medical Inc.

, /PRNewswire/ -- Rapha Capital Management, LLC (), an investment management firm located in , through Rapha Capital Investment IX, LLC ("RCI IX") (an entity managed by Rapha Capital), led FIZE Medical...

BLCM : 8.78 (-1.35%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of...

BLCM : 8.78 (-1.35%)
Bellicum Pharmac Shares Up 24.7% Since SmarTrend's Buy Recommendation (BLCM)

SmarTrend identified an Uptrend for Bellicum Pharmac (NASDAQ:BLCM) on March 30th, 2020 at $4.89. In approximately 2 weeks, Bellicum Pharmac has returned 24.74% as of today's recent price of $6.10.

BLCM : 8.78 (-1.35%)
Bellicum Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020...

BLCM : 8.78 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade BLCM with:

Business Summary

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product...

See More

Key Turning Points

2nd Resistance Point 9.94
1st Resistance Point 9.36
Last Price 8.78
1st Support Level 8.40
2nd Support Level 8.02

See More

52-Week High 27.90
Fibonacci 61.8% 18.51
Fibonacci 50% 15.61
Fibonacci 38.2% 12.71
Last Price 8.78
52-Week Low 3.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar